[Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors].
Bläker
M
M
I. Medizinische Klinik und Poliklinik, Zentrum für Innere Medizin, Universitätsklinikum Hamburg-Eppendorf. blaeker@uke.uni-hamburg.de
de Weerth
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D004338:Drug Combinations; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000627:therapeutic use*; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D053379:Chromogranin A; D002864:Chromogranins; D004338:Drug Combinations; D016898:Interferon-alpha; D019394:Ki-67 Antigen; D006897:Hydroxyindoleacetic Acid; D015282:Octreotide